医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Fujifilm Completes Acquisition of Irvine Scientific Sales Company and IS Japan, Leading Companies of Cell Culture Media

2018年06月05日 PM06:31
このエントリーをはてなブックマークに追加


 

SANTA ANA, Calif.

FUJIFILM Corporation (President: Kenji Sukeno) announced today that it has completed the acquisition of Irvine Scientific Sales Company, Inc. (ISUS) and IS JAPAN CO.,LTD. (ISJ), leading companies in cell culture media for about US$800 million on June 1 in the United States.

To advance its growth strategies in the healthcare area, Fujifilm continues to invest in contract development and manufacturing of biopharmaceuticals and regenerative medicine. At FUJIFILM Diosynth Biotechnologies (FDB), manufacturing capacity for antibody drugs has been increased. FUJIFILM Cellular Dynamics (FCDI), a world-class developer and manufacturer of iPS cell technologies and know-how, is now a wholly owned subsidiary, and to enter the cell culture media business, Fujifilm acquired FUJIFILM Wako Pure Chemical, a leading reagent manufacturer.

With the acquisition of ISUS and ISJ, Fujifilm will now be able to provide a broad product portfolio from biopharmaceuticals to in vitro fertilization and cell therapy, strengthening its global business in addition to expanding domestic business through strong sales network in Japan. Utilizing its advanced chemical synthesis and design capabilities cultivated in the photographic film business and the cell preparation and culturing technologies of its group companies such as Japan Tissue Engineering, FCDI and FDB, Fujifilm will accelerate the development of highly competitive cell culture media, supporting the further growth of its cell culture media business. Further, by combining the Fujifilm Group’s bio-medical-related technologies and products with the cell culture media technologies and products of ISUS and ISJ, the company will expand the contact development and manufacturing business for biopharmaceuticals and reagent business, and also accelerate research and development in the area of regenerative medicine.

<Company Overview of ISUS and ISJ> (As of June 5, 2018)

    ISUS   ISJ
Company Name Irvine Scientific Sales Company, Inc. IS JAPAN CO.,LTD.
Location Santa Ana, California, U.S.A. Toda, Saitama, Japan
Year of incorporation 1970 1989
CEO Yutaka Yamaguchi Masatoshi Kato
Shareholder FUJIFILM Holdings America Corporation(100%) FUJIFILM(100%)

ENDS

For a high-resolution image please contact lorna.cuddon@zymecommunications.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20180605005803/en/

CONTACT

Irvine Scientific
Lori Serles
Phone: 949-261-7800 x145
Email:
lserles@irvinesci.com
or
Zyme
Communications

Lorna Cuddon
Phone: +44 (0)7811996942
Email:
lorna.cuddon@zymecommunications.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • CANbridge Life Sciences Receives Approval to Commence CAN017 Ib/III Trial in Esophageal Squamous Cell Cancer (ESCC) In China
  • AVEO Announces Acceptance of CANbridge Investigational New Drug Application for CAN017 (AV-203) Trial in Esophageal Squamous Cell Cancer (ESCC) in China
  • STAAR Surgical and Shinjuku LASIK Clinic in Japan Announce Strategic Cooperation Agreement
  • 新研究调查诊断性多通道睡眠检查之前采用Masimo SET®脉搏氧饱和度仪居家监测筛查唐氏综合征患儿罹患阻塞性睡眠呼吸暂停的风险
  • ダウン症候群の小児を対象とする睡眠時障害診断のマルチチャンネル研究に先立つ閉塞性睡眠時無呼吸症リスクのスクリーニングとしてMasimo SET®パルスオキシメトリーを使用するホームモニタリングの有用性を検討する新研究